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Abstract  
Introduction.  Patients with chronic headache who consume large amounts of analgesics are often 
encountered in clinical practice.  Excessive intake of analgesics is now considered to be a cause, rather 
than simply a consequence of frequent headaches, and as such the diagnosis “medication overuse 
headache” has been formulated.  Despite the prevalence and clinical impact of medication overuse 
headache the pathophysiology behind this disorder remains unclear and specific mechanism-based 
treatment options are lacking. 
Discussion.  Although most acute headache treatments have been alleged to cause medication overuse 
headache, here we conclude from the literature that opioids are a particularly problematic drug class 
consistently associated with worsening headache.   Medication overuse headache may not be a single 
entity, as each class of drug implicated may cause medication overuse headache via a different 
mechanism.  Recent evidence indicates that chronic opioid administration may exacerbate pain in the 
long-term by activating Toll-Like Receptor-4 on glial cells, resulting in a pro-inflammatory state that 
manifests clinically as increased pain.  Thus, from the available evidence it seems opioid overuse 
headache is a phenomenon similar to opioid-induced hyperalgesia, which derives from a cumulative 
interaction between central sensitisation, due to repeated activation of nociceptive pathways by 
recurrent headaches, and pain facilitation due to glial activation. 
Conclusion. Treatment strategies directed at inhibiting glial activation may be of benefit alongside 
medication withdrawal in the management of medication overuse headache. 
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Introduction 
Patients with a prior history of a primary benign headache disorder who develop chronic daily headache 
associated with high frequency of analgesic intake form a high proportion of patients at specialist 
headache clinics.
1-4
  Over the past few decades it has been proposed that excessive intake of analgesics 
and/or other symptomatic headache treatments may actually be a cause, rather than simply a 
consequence of frequent headaches, and as such the disorder “medication overuse headache” is 
recognised in the International Classification of Headache Disorders.   Opioid analgesics in particular 
appear to be strongly associated with the development of medication overuse headache (MOH).
5
  Little 
is known in regard to the pathophysiology of MOH,
6
 thus mechanism-based specific treatments are 
lacking.  Current practice is to withdraw the overused medication, a process that can be considerably 
distressing and difficult for patients, sometimes requiring hospital admission. 
MOH in patients consuming opioids is likely to share pathophysiological features with opioid-induced 
hyperalgesia, a phenomenon in which opioids paradoxically increase pain sensitivity.  The relatively 
recent discovery that microglia and astrocytes are able to facilitate nociceptive transmission once 
activated following opioid exposure provides a possible mechanism for the characteristic exacerbation 
of headache seen in this disorder.  Drugs that target glial attenuation therefore represent novel 
treatment strategies that may be able to reduce headache burden and make detoxification procedures 
easier and more successful. 
 
Medication overuse headache 
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According to the revised second edition of the International Classification of Headache Disorders, MOH 
should be diagnosed in patients with A) headache on ≥ 15 days per month, B) regular overuse of acute 
headache treatments for > 3 months and C) for whom headache has developed or has markedly 
worsened during medication overuse.
7
  MOH is not a unitary entity, thus the threshold defining 
‘overuse’ is dependent upon the class of drug consumed.  Medication intake on ≥ 10 days per month is 
considered overuse for ergotamine, triptans, opioids and combination preparations, whereas intake on 
≥ 15 days per month is required to meet the criteria for overuse of simple analgesics (non-steroidal anti-
inflammatory drugs (NSAIDs), including aspirin, and paracetamol) or a combination of acute headache 




MOH is a global health issue which impacts significantly on the quality of life of affected individuals, and 
imposes a large economic burden upon society.
9
  It is reported to be the third most common form of 
headache encountered in clinical practice, following only tension-type headache and migraine,
10, 11
 
accounting for between 25-60% of patients seen in specialist headache centres.
1, 2, 11, 12
 
Although medication overuse is a known risk factor, alone it is neither necessary nor sufficient to induce 
chronic daily headache.
13
 When patients receive opioids or other analgesics for non-headache 
indications, those without a history of headache do not develop MOH, whereas those with a history of 
episodic headache frequently progress to experience chronic daily headache.
14, 15
 
Causative agents in MOH 
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While virtually all drugs used in the symptomatic treatment of headache have been reported to induce 
MOH 
16
 from the primary literature it is clear that opioids are one medication class most strongly 
associated with progression to chronic headache.    
In both clinic-based studies and longitudinal population-based studies, opioids are consistently 
associated with the development of chronic daily headache.
15, 17, 18
  As part of the American Migraine 
Prevalence and Prevention study, the probability of transformation from episodic migraine to chronic 
migraine over one year was modelled in relation to medication use, using paracetamol users as a 
reference group.  In unadjusted analyses, preparations containing opioids doubled the risk of chronic 
migraine, while medications such as triptans and NSAIDs did not significantly increase the likelihood of 
headache transformation.  The probability of progression to chronic migraine was also found to 
correlate with elevated monthly opioid dose.
18
  Barbiturate use is also associated with headache 
progression,
18
 however MOH remains highly prevalent in territories where barbiturates are not longer 
used in headache management.  These findings are supported by the results of the Frequent Headache 
Epidemiology study which found that opioid use, following adjustment for age, sex, primary headache 
diagnosis and number of pain medications consumed, was significantly associated with chronic daily 
headache, whereas use of aspirin or ibuprofen was in fact protective against headache progression.
17
  
To assess the hypothesis that opioids play a definitive role in inducing MOH, Bigal and colleagues have 
also employed Hills criteria of causation to demonstrate that a causal relationship between excessive 
opioid use and progression from episodic migraine to chronic daily headache is plausible.
5
 
Pathophysiology of MOH 
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Despite the high prevalence and clinical impact of MOH the mechanisms contributing to the 
development of this disorder remain unclear.
19
  While current research suggests several factors could 
play role in the pathophysiology of MOH, at present it is only possible to summarise mechanisms that 
appear to be associated with, or may predispose patients to, this condition.
6, 16
  Insights gained from 
preclinical studies have been discussed recently in comprehensive reviews by Meng and colleagues
20
 
and Bongsebandhu-phubhakdi and Srikiatkhachorn.
21
  Clinically, it seems that both behaviour and 
biology contribute to the initiation and maintenance of MOH and successful long-term treatment of this 
disorder depends upon adequate treatment of both elements.
22
 
Psychological and behavioural factors.  A number of psychological states and behaviours appear to 
be important in the development and perpetuation of medication overuse.  Such factors include anxiety 
disorders, depressive disorders and obsessional drug-taking and/or dependence-related behaviours.
22, 23 
Genetic studies.  A hereditary susceptibility to MOH, and therefore a genetic component to the 
pathogenesis of this disorder, has been proposed on the basis of epidemiological data.
6
  The risk of 
developing MOH appears almost three times greater in individuals with a family history of MOH,
24
 and 
further to the hypothesized link between substance abuse/dependence and MOH, patients with MOH 
are also more likely to have relatives who suffer from drug overuse or substance abuse.
24
  A small 
number of studies have investigated potential molecular genetic factors related to dopamine and 
serotonin transport or substance abuse that may be involved in MOH,
25-28
  yet at present this knowledge 
has not lead to the identification of new treatment targets. 
Endocrine and neurotransmitter abnormalities.  Depletion of serotonin (5HT) in platelets29 and up-
regulation of the pro-nociceptive 5HT2 receptor
30
 have been demonstrated in MOH.  Furthermore, in a 
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small pilot study, 5HT blood levels in MOH patients were reported to increase significantly following 
withdrawal of the overused analgesics, corresponding with clinical headache improvement.
31
  It has 
been hypothesised that further suppression of an already abnormal 5HT-dependent antinociceptive 
system in patients with pre-existing headache by analgesic overuse may lead to the headache 
chronification seen following medication overuse.
32
 
The endocannabinoid system has also been investigated in related to MOH as it is involved in 
modulating pain and plays a role in addiction and reward.
33
  The activity of an endocannabinoid 
membrane transporter
33




Few studies have looked at the endocrine function of patients with MOH.  Increased levels of orexin-A 
and corticotrophin-releasing hormone were found in the cerebrospinal fluid of patients with MOH, and 
these levels were correlated with monthly drug intake and dependence scores on a self-completed 
questionnaire.
35
  The authors suggest such results could be interpreted as either a compensatory 
response to chronic pain or a hypothalamic response to stress deriving from the chronic pain.
35
 Opioids, 
especially at high doses, cause suppression of gonadotrophin secretion and cortisol release.
36-38
   One 
study in MOH patients, who did not take opioids, showed reduced growth hormone and 
thyroid-stimulating hormone response and increased adrenocorticotropic hormone and cortisol 
responses compared to controls.
39
  However, endocrine responses specifically in opioid overuse 
headache have not been reported. 
Acquired central sensitisation.  There is growing evidence that central sensitization plays a significant 
role in the general process of headache chronification.  Several features of chronic daily headache, 
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including increased headache frequency, expansion of the headache area and cutaneous allodynia, 
which are often observed in MOH, imply sensitisation of the trigeminal nociceptive neurons.
40
  In MOH, 
facilitation of pain processing has been established in a range of studies using psychophysical and 
electrophysiological techniques.  Recently Perrotta and colleagues found the threshold and temporal 
summation threshold of the nociceptive withdrawal reflex to be markedly reduced in patients with 
MOH. Psychophysical measurements also exposed enhanced pain perception following single and 
repeated stimulation in MOH patients as compared to episodic migraineurs.  It appears the 
abnormalities observed were related, at least in part to medication overuse, as withdrawal of the 
overused medication was associated with an improvement in neurophysiological findings.
19
  Ayzenberg 
and colleagues also observed pain facilitation of trigeminal and somatic nociceptive systems in MOH 
patients, which normalized after withdrawal treatment.
41
 
Pharmacological factors.  In addition to the above endogenous factors, causative mechanisms by 
which the wide range of agents alleged to cause MOH need to be elucidated.  Although there may be a 
unifying mechanism by which structurally and pharmacologically unrelated analgesics may promote 
central sensitisation, it may be that different mechanisms exist for differing drugs and groups of drugs.  
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It is well known that tolerance and dependence develop after prolonged exposure to opioids and there 
is extensive literature on the neuronal mechanisms involved in these phenomena.
42-45
 More recently, an 
additional unwanted consequence of opioid use which may contribute to reduced opioid efficacy, a 
paradoxically enhanced sensitivity to pain termed opioid-induced hyperalgesia,
46
 has been 
demonstrated in animals and suggested in some human studies.  Opioid-induced hyperalgesia has been 
defined by controlled, pre-clinical animal studies as a reduction in pain threshold from baseline 
following extended exposure to opioids.
47
  In a clinical context it has been described as increased 
sensitivity to stimuli that normally provoke pain or a general exacerbation of pain in the absence of new 
tissue damage, subsequent to opioid intake.
46
  
Pre-clinical evidence of opioid-induced nociceptive sensitivity 
Many laboratories have clearly demonstrated thermal hyperalgesia and/or mechanical allodynia 
following both acute and chronic administration of opioids, including morphine, heroin, fentanyl and 
remifentanil, using a range of animal models
48-52
 
Clinical evidence of opioid-induced hyperalgesia 
While opioid-induced hyperalgesia is well documented in pre-clinical models, data from human studies 
remain controversial, as conflicting results have been reported.
46
  Clinical and experimental evidence of 
opioid-induced hyperalgesia in man derives from studies in a number of diverse populations, namely, 
chronic pain patients receiving long-term opioid therapy, patients receiving peri-operative opioids, 
53
 
opioid-addicted or maintained patients
54, 55
  and healthy volunteers taking part in investigational studies 
using experimental pain models, although the demonstration of OIH may be model-dependent.
56
  A 
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recent systematic review which evaluated clinical studies investigating opioid-induced hyperalgesia 
found that the strongest evidence supporting the existence of opioid-induced hyperalgesia came from 
studies in healthy volunteers, which involved assessment of secondary hyperalgesia following an opioid 
infusion.
47
  In this review the authors conclude that evidence to date is insufficient to either support or 
refute the existence of opioid-induced hyperalgesia in humans, with the exception of opioid-induced 
hyperalgesia precipitated by opioid infusions in healthy volunteers.
47
 However, the extent to which 
these experimental findings relate to clinical practice remains unclear. 
Opioid-induced hyperalgesia in chronic pain patients receiving opioids.  Chronic pain patients 
often experience a reduction in opioid analgesic efficacy over time, which may at least in part be due to 
opioid-induced hyperalgesia in additional to tolerance.
57
  A range of individual cases and case series 
have described hyperalgesia associated with opioid administration and a reduction in pain following 
detoxification from the causative opioid medication.
58-63
  At least two studies have prospectively 
evaluated the association between opioid dose and hyperalgesia in chronic pain patients, observing the 
development of hyperalgesia when initiating opioid treatment and increases in pain thresholds 
following opioid tapering. 
64, 65
   However, more recent evidence from one of these groups in a large 




Codeine and opioid-induced hyperalgesia 
To date there are no pre-clinical or clinical published data examining whether codeine can cause 
opioid-induced hyperalgesia.  Our group conducted a small pilot trial comparing the cold pain tolerance 
and thresholds of non-headache pain patients receiving on average 83 mg (range 30-180 mg) of codeine 
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daily for 3 months or more with a control group of chronic pain patients taking paracetamol and/or non-
steroidal anti-inflammatory drugs.
67
  In this cohort hyperalgesia was not observed, yet this may be a 
result of our modest sample size.
67
 
While larger doses of opioids more commonly lead to opioid-induced hyperalgesia, both ultra-high and 
ultra-low doses of opioids have been reported to cause nociceptive sensitization.
68
 Thus, despite the 
fact that only a small fraction of the pro-drug codeine converted in the body to morphine
69
 it is plausible 
that it too has potential to enhance pain sensitivity.  This is important in terms of our hypothesis as 
many headache patients develop MOH following the overuse of combination analgesics that contain 
codeine
11, 70, 71
 on a background of repeated glial activation due to recurrent headaches. 
Possible mechanisms of opioid-induced hyperalgesia 
Whilst opioid-induced hyperalgesia was first reported in a peer-reviewed journal over 60 years ago,
72
 
the molecular mechanisms and pathophysiology underlying this disorder remain unclear.  Many 
hypotheses regarding the development of opioid-induced hyperalgesia have been put forward, including 
sensitization of peripheral nerve endings or second order neurons, enhanced descending facilitation of 




Many studies investigating the mechanisms involved in opioid-induced hyperalgesia have focused upon 
the increased amounts of or responses to various excitatory neurotransmitters through neuroplasticity, 
often examining the role of the glutaminergic N-methyl D-aspartate (NMDA) receptor.
46
  In pre-clinical 
studies  NMDA antagonists such as ketamine, magnesium and the experimental compound MK-801  
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prevent and/or reverse hyperalgesia  following exposure to sufentanil or fentanyl.
73-75
 Alternatively, it 
has been speculated that biologically active glucuronide metabolites may play a role in 
morphine-induced hyperalgesia.
76, 77
  The metabolite morphine-3-glucuronide, which is known to 
possess very little affinity for any of the opioid receptor subtypes,
78, 79
 is able to stimulate potent 
neuro-excitatory effects on behaviour when administered to rodents,
80, 81
 yet this hypothesis does not 
explain opioid-induced hyperalgesia following administration of opioids which do not form glucuronide 
metabolites such as fentanyl.
75
 
Although in the past it has been postulated that opioid receptor activation is a prerequisite for 
opioid-induced hyperalgesia, triple knock out mice lacking μ, δ and κ opioid receptors or rodents 
concurrently receiving the opioid receptor antagonist naltrexone also develop opioid-induced 




Each of the studies discussed above, and the vast majority of the literature investigating opioid-induced 
hyperalgesia, has focused upon neuronal mechanisms by which opioids may increase pain sensitivity.  
However, in more recent times the pivotal role of neuroimmune activation and neuroinflammation in 
the pathogenesis of opioid-induced hyperalgesia has been described.
82
 
Neuroimmune interactions in pain 
Traditionally our understanding of pain has focused almost exclusively upon neurons, as neuronal 
circuits are fundamental in the processing, integration and transmission of nociceptive signals.
83
 
Recognition of the importance of neuroimmune interactions has come to provide a significant 
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conceptual advance in the understanding of nociceptive processing
84
 and thus, has brought to light 
many novel targets with the potential to further improve the clinical management of pain. 
Over the last two decades evidence has been mounting that astrocytes and microglia, in addition to 
neurons, play a vital role in pain modulation, including the initiation and maintenance of pathological 
pain.
85-87
  It is likely that other glial cell types are also involved in pain facilitation, however research to 
date has focused upon astrocytes and microglia, as they are the most amenable to study.
88, 89
  
An incontrovertible wealth of pre-clinical data show when exposed to stimuli, such as central nervous 
system (CNS) trauma, ischaemia, neurodegeneration or the immunological components of pathogens, 
microglial cells rapidly become ‘activated’, i.e. they develop an ability to perform a function beyond that 
which they are able to perform in the baseline state.
90
  Subsequently, astrocytes become activated in 




Activation of astrocytes and/or microglia translates to increased production of mediators such as 





, arachidonic acid and prostaglandins, excitatory amino acids, adenosine 
triphosphate, reactive oxygen species, nitric oxide and nerve growth factors.
92
  Such inflammatory 
substances are able to increase neuronal excitability both directly and indirectly. 
92
. In addition to the 
neuronal effects, these pro-inflammatory mediators also stimulate further glial cells, generating a 
positive feedback loop.  After a stimulus has resolved, experimental evidence suggests microglia remain 
“primed”, entering a sensitised state in which they do not actively produce pro-inflammatory 
substances, yet they over-respond to subsequent stimuli, increasing pro-inflammatory cytokine release 




Activation of spinal microglia and astrocytes has been demonstrated in virtually every clinically relevant 
animal model of an enhanced pain state
88
 with similar results reported for trigeminal pain models.
97
  
Moreover, glial-attenuating pharmacological interventions are able to block the phenotypic 
transformation of glial cells into the activated state and prevent both allodynia and hyperalgesia across 
a diverse range of pre-clinical pathological pain models.
98-103
 
It is now clear that glia-to-neuron signaling via toll-like receptor 4 (TLR-4) can play a causal role in the 
initiation and maintenance of pathological pain.
104-107
 The toll-like receptors (TLRs) are a family of innate 
immune pattern recognition receptors, which respond to a wide variety of pathogen-derived and tissue 
damage-related ligands.
108
  The TLR-4 receptor, which is primarily expressed upon microglia,
109
 is an 
important contributor to activation of these cells, although expression on astrocytes, endothelial cells 
and neurons has also been reported.
110, 111
  For a complete review of the role of TLRs in chronic pain, see 
review by Nicotra et al.
112
 
The relevance of TLR signalling in human pain states is currently unknown largely due to the 
inaccessibility of pertinent tissue. Recently we have documented indirect evidence of clinical TLR 
involvement by studying peripheral blood mononuclear cells (PBMCs), which share many similarities 
with immune cells of the CNS.
113
 PBMCs were isolated from human samples, stimulated ex vivo with TLR 
agonists and the subsequent release of IL-1β was measured. PBMCs from chronic pain patients released 
a significantly higher amount of TLR agonist stimulated IL-1β, as compared to that of pain-free 
individuals, and was higher again in chronic pain patients on opioids. These findings are, suggestive of 
immune alterations in human pain states and enhancement by opioids. 
114
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Opioid-Induced Glial Activation 
Glial activation is now also known to occur in response to opioid exposure.
107
  Pre-clinically 
opioid-induced glial activation is known to oppose opioid analgesia and enhance opioid adverse effects 
including tolerance, dependence, reward and respiratory depression.
115, 116
 Interestingly, opioid-induced 
glial activation is mediated through activation of TLR-4, exposing the potential to separate the beneficial 
actions of opioids from their unwanted adverse effects.
92
  Pre-clinical studies have demonstrated that 
while morphine administration results in analgesia via agonism at the μ-opioid receptor on the neurons, 
it is also activates glial cells via TLR-4, resulting in the production of neuroexcitatory mediators.
117
  The 
initial additive result is a reduction in pain, yet with prolonged opioid administration glial activation 
increases, as does subsequent pain facilitation, working against the analgesic effects of morphine, 
presenting clinically as opioid tolerance and then hyperalgesia.
118
  This dual activity at both neuronal 
and glial cells is common with other clinically relevant opioids.
115
 It has recently been demonstrated that 
morphine-3-glucuronide has TLR-4 agonist activity, indicating that codeine and morphine metabolites 
may contribute to this action.
119
  For a detailed discussion regarding the role of TLR-4 in opioid-induced 
glial activation see review by Watkins at al.
92
  
Despite the established body of pre-clinical evidence human trials are yet to conclusively demonstrate 




Pro-inflammatory central immune signalling hypothesis of MOH  
Johnson et al.   2012   Version 2, resubmitted 03/SEP/2012    Page 17 of 37  
As discussed previously, headache pain resulting from regular consumption of opioid analgesics is a 
complication specific to patients with pre-existing headache, indicating there is a unique predisposing 
factor among this population.
14, 120
  Within this group of MOH patients, the vast majority first present 
with episodic migraine or tension-type headache
121
 as opposed to other forms of primary headache 
such as cluster headache.
122
  We hypothesise this selective propensity to develop MOH stems from 
altered pro-inflammatory central immune signalling in patients with migraine and tension-type 
headache, or the presence of underlying central sensitisation, which renders them particularly 
susceptible to the effects of opioid-induced glial activation. 
Evidence from preclinical models supports a role for neuron to glia interactions in migraine pain.
123
  Glial 
cells are known to release a range of inflammatory cytokines, such as IL-1β, IL-6 and fractalkine, when 
exposed to calcitonin gene-related peptide (CGRP), a product released by neurons during migraine.
123
  
The cumulative glial activation resulting from CGRP release and opioid exposure is likely to be greater 
than that caused by CGRP alone, potentially explaining the exacerbation of migraine pain following 
opioid use. 
The role of the immune system and central immune signalling in particular in tension-type headache is 
less clear.  However, tension-type headache is generally considered a disorder of acquired central 
sensitisation of unknown cause,
124
 thus, regardless of the source, the nociceptive sensitivity originally 
exhibited by this patient group could predispose them to headache chronification due to further pain 
facilitation brought about by opioid-induced glial activation.  Of note, the tricyclic antidepressant 
amitriptyline, is the principal drug with proven efficacy in the prophylactic treatment of tension-type 
headache
125
 but its mechanism of action is this condition is unclear
126
.  Recently amitriptyline has been 
found to possess strong TLR-4 inhibitory activity.
107
  While amitriptyline does not alter baseline pain 
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sensitivity it is able to potentiate morphine analgesia, as are other inhibitors of TLR-4 signalling.
107
  
These findings raise the possibility that attenuation of glial activation via TLR-4 blockade could 
contribute to the efficacy of this medication in tension-type headache. 
The secretion of cytokines and other pro-inflammatory mediators, such as IL-1β, IL-6, TNF-α and nitric 
oxide, by activated glial cells seems likely to play a role in the transformation of episodic headache to 
chronic headache in general, and to MOH in particular as discussed by Meng and Cao.
127
  This review 
also highlights the ability of stressful life events to amplify pain signals and contribute to headache 
chronification via glial activation.
127
  Tumor necrosis factor-α, a substance released by activated glia 
known to mediate chronic pain states, is elevated in chronic headache patients with both migrainous 
and tension-type headache phenotypes.
128
 and serum S100β, a protein derived from glial cells, is also 
raised in children with migraines.
129
  Moreover, a study which identified a unique genomic expression 
pattern in MOH patients that responds to medication withdrawal used gene ontology of the samples 
obtained to determine that a significant number were involved in brain and immunological tissues, 
including the TLR signaling pathway, again alluding to altered immune activity in MOH.
130
 
It is likely that opioid-overuse headache is related to opioid-induced hyperalgesia and is similarly 
mediated by glial activation in a susceptible patient population.  It is plausible that opioid overuse may 
only lead to chronic headache in patients with pre-existing headache disorders, as the glial cells of 
headache suffers may be primed for activation, due to either repeated exposure to nociceptive signals 
as a consequence of the headache condition, or an underlying immune abnormality.  Alternatively 
central sensitisation could increase the baseline pain sensitivity in these patients and further pain 
facilitation due to opioid-induced glial activation may be sufficient to transform episodic bouts of 
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headache into chronic headache disorder.  See Figure 1 for a diagrammatical representation of the 
hypothesis. 
Figure 1. (a) Neurons in basal state & glial cells quiescent. (b) Recurrent nociceptive impulses during 
episodic headaches sensitise neurons which release pro-inflammatory mediators that activate glial cells. 
Activated glial cells then release further pro-inflammatory mediators increasing pain sensitivity & 
headache frequency.  After stimulus ceases glia remain primed. (c) Patient consumes opioids. Opioids 
agonise μ-opioid receptor to reduce pain. Opioids bind to TLR-4 to activate glia. Pro-inflammatory glial 
response is exaggerated as glial cells are primed. Long-term the net result is pain facilitation leading to 
chronic headache. (d) Ibudilast attenuates glial activation to reduce pain facilitation. μ-opioid receptor 
effects are not altered. Reduction in pain breaks cycle of opioid intake/glial activation/increased 
headaches.  Abbreviations: IL-1β: interleukin 1β, IL-6: interleukin 6, TNFα: tumor necrosis factor α, ROS: 
reactive oxygen species, PGs: prostaglandins, NO: nitric oxide, EAA: excitatory amino acids, TLR-4: 
toll-like receptor 4. 
Glial involvement in headache following opioid exposure has been evaluated pre-clinically using a 
rodent model of headache and morphine administration.  In this study the authors were able to 
demonstrate that pre-exposure to an opioid results in facial allodynia, a surrogate for headache pain, 
during application of inflammatory “soup” to the dura in doses that fail to produce allodynia in 
opioid-naïve rats.
131
  When low-dose inflammatory soup was applied following morphine administration 
but prior to a dose of inflammatory soup able to reliably produce robust facial allodynia, no pain 
facilitation was observed, mirroring the clinical observation that MOH does not develop de novo in 
those without a pre-existing headache condition.
131
  The exacerbation of head pain observed was 
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attributed to opioid-induced glial activation as co-administration of the glial attenuator ibudilast with 
morphine was able to prevent facial allodynia.
132
 
We have conducted docking simulations to explore the possibility that other headache treatments could 
activate glial cells, as opioid do, to worsen headache.  In silico docking assessments using Vina133 and 
previously published TLR4/Myeloid differentiation protein-2 (MD2) pdb files, indicate the energy 
requirement for codeine to bind to MD2, a protein required for TLR-4 activation, is over 100 fold lower 
than that of paracetamol, ibuprofen, sumatriptan and butabarbital.  Furthermore, the non-codeine 
headache drugs bind at a site that is not characterised as important in the activation of the TLR-4/MD2 
complex, indicating they are unlikely to trigger glial activation. 
Taken together these findings  suggest TLR-4 mediated glial activation may be specific to opioids among 
headache treatments and hence may be amenable to specific therapy directed to this pathway. 
Potential treatment strategies targeting glial activation 
From the arguments given above, we propose that pharmacological approaches that aim to control glial 
regulation of nociception may be of benefit in the clinical management of opioid overuse headache.  
Although it is agreed that medication withdrawal is essential, it is recognised that in many patients 
withdrawal is difficult but can be achieved through a comprehensive, multidisciplinary approach. 
134
  
However, there is controversy whether this is the only treatment approach,
135
 or whether additional 
medication can reduce headache burden before medication withdrawal to make the process easier.
136
 
Currently no drug available for human use was developed specifically to target glial cells,
90
 however a 
number of medications marketed for other indications have been found to attenuate activated glia and 
therefore may represent novel treatments for MOH.  Conventional immunosuppressive agents are 
unlikely to be beneficial in the management of MOH because of paradoxical TLR activation.
137
  The 
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medications licensed for use in humans for other conditions that have been shown to have glial 
inhibitory properties include minocycline and ibudilast.  
Minocycline, a tetracycline derivative that possesses anti-inflammatory effects that are independent of 
its antimicrobial actions;
90
 selectively disrupts activation of microglial cells to prevent allodynia without 
directly effecting either astrocytes and neurons.
138
 Given that it is an already licenced, reasonably 
tolerated drug it could be considered as a treatment worth exploring for opioid overuse headache.  
However  animal studies suggest that minocycline only has a significant inhibitory effect on glia when 
given before glial stimulation and is far less effective in reversing enhanced pain states, relative to drugs 
that also inhibit astrocyte activity.
138, 139
  These properties do not make it appealing for treating existing 
opioid overuse headache.  
Ibudilast, a relatively non-selective phosphodiesterase inhibitor that has been licensed for more than 20 
years in Japan for the treatment of asthma,
140
 may be a more promising treatment option for opioid 
overuse headache.  In recent times it has been found to have glial attenuating properties, in particular 
the ability to inhibit TLR-4 signalling
117
 and, unlike minocycline, it is effective in reversing allodynia when 
given after the glial activating stimulus.
102




Emerging data from human studies also support the use of ibudilast in neuroinflammatory conditions.  A 
2 year clinical trial in multiple sclerosis provides some evidence that ibudilast has activity in the brain as 
it was able to reduce white matter loss.
142
   Intriguingly and of relevance, although no conclusions can 
be made regarding efficacy in headache, a recent trial (clinicaltrials.gov identifier NCT00723177) has 
produced encouraging results following administration of ibudilast to human opioid addicts.
143
  During 
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this double-blind, placebo-controlled study, heroin dependent subjects were able to withdraw from 
opioids with greater easer when receiving ibudilast,
143
 indicating ibudilast may play a role in reversing 
the adaptive changes associated with long-term opioid use.  Ibudilast doses used in these trials (up to 




  We are currently conducting a randomised, double-blind, 
placebo-controlled trial of ibudilast in the treatment of MOH in patients who overuse opioids, see 
clinicaltrials.gov identifier NCT01317992 for more information regarding this study. 
Ideally however a new drug with glial inhibitory properties that is without other actions would be most 
appropriate for evaluation.  One potential candidate is (+)-naltrexone.  This enantiomer of the orally 
available long acting selective -receptor antagonist (-)-naltrexone, which is licensed for use in humans 
for the management of opioid and alcohol addiction, is devoid of -receptor antagonism but is a potent 
TLR-4 antagonist.  In preclinical studies (+)-naltrexone has been found to potentiate acute morphine 
analgesia, block opioid reward,
144





.  Studies to enable its use in humans are currently in progress. 
Summary 
MOH remains a significant clinical problem worldwide.  Opioids are strongly associated with, and 
probably causally related to, the development of MOH.  There is convincing preclinical evidence that 
opioids cause hyperalgesia through activation of glial cells via TLR-4 stimulation.  Furthermore, evidence 
is emerging that in humans chronic pain is associated with increased TLR-4 sensitivity.  This provides 
sufficient evidence to trial glial attenuators and/or TLR-4 antagonists as a potential disease-modifying 
treatment options in this area of high unmet medical need. 
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